In April 2025, Source BioScience acquired Cambridge Clinical Laboratories (CCL), a leading Cambridge-based provider of personalised healthcare testing services. CCL delivers specialist diagnostic solutions across oncology, virology and hereditary, alongside validation studies for clinical research.
The acquisition expands Source Genomics’ clinical diagnostics portfolio and strengthens their position as a provider of comprehensive, end-to-end laboratory services.
